

Sandra MiliÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12031575/publications.pdf>

Version: 2024-02-01

23
papers

1,539
citations

623574

14
h-index

677027

22
g-index

23
all docs

23
docs citations

23
times ranked

2891
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. <i>World Journal of Gastroenterology</i> , 2014, 20, 9330-7.	1.4	328
2	Transient elastography (FibroScan [®]) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7236.	1.4	193
3	Vitamin D Deficiency: Consequence or Cause of Obesity?. <i>Medicina (Lithuania)</i> , 2019, 55, 541.	0.8	175
4	Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. <i>Digestive Diseases</i> , 2012, 30, 158-162.	0.8	165
5	Nonalcoholic fatty liver disease - A multisystem disease?. <i>World Journal of Gastroenterology</i> , 2016, 22, 9488.	1.4	148
6	The Role of Iron and Iron Overload in Chronic Liver Disease. <i>Medical Science Monitor</i> , 2016, 22, 2144-2151.	0.5	133
7	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2018, 24, 1491-1506.	1.4	95
8	Prognostic Values of IL-6, IL-8, and IL-10 in Acute Pancreatitis. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 209-212.	1.1	64
9	Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4835.	2.0	53
10	Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1347-1353.	1.2	43
11	Nonalcoholic fatty liver disease (NAFLD) – a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. <i>Clinical Interventions in Aging</i> , 2014, 9, 1295.	1.3	27
12	Nonalcoholic Fatty Liver Disease (NAFLD) “A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 427-432.	1.1	20
13	Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events?. <i>Blood Purification</i> , 2014, 37, 259-265.	0.9	18
14	Metabolic syndrome and non-alcoholic fatty liver disease after liver or kidney transplantation. <i>Hepatology Research</i> , 2016, 46, 841-852.	1.8	16
15	Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 474-479.	1.0	13
16	Non-Alcoholic Fatty Liver Disease and COVID-19 “Two Pandemics Hitting at the Same Time. <i>Medicina (Lithuania)</i> , 2021, 57, 1057.	0.8	13
17	Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation. <i>Liver International</i> , 2017, 37, 1113-1115.	1.9	10
18	Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 428-437.	0.7	8

#	ARTICLE	IF	CITATIONS
19	Advances in diagnosis of chronic liver diseases in pediatric patients. World Journal of Pediatrics, 2018, 14, 541-547.	0.8	7
20	IL-6 is Valuable Prognostic Indicator in Acute Pancreatitis. Journal of Clinical Gastroenterology, 2007, 41, 534-535.	1.1	4
21	Non-alcoholic fatty liver disease and transient elastography. Exploration of Medicine, 2020, 1, 205-217.	1.5	4
22	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina (Lithuania), 2022, 58, 252.	0.8	2
23	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. Acta Clinica Croatica, 2021, 60, 36-52.	0.1	0